The Pharma Navigator discusses the increasingly complex therapeutic landscape and how strategic partnerships can be beneficial with Dr. Srinivasan Shanmugam from Adare, and finds out more about the company’s plans for CPHI Americas with Steven Facer, Senior Vice President, Global Sales and Marketing.

As the month of May marches on, the city of Philadelphia prepares itself to once again play host to CPHI — this year under its new guise of CPHI Americas. For 2025, the event organizers have updated the name of the show to reflect the broader audience, which incorporates Latin America and Canada in addition to North America.

The oral combination therapy has been shown to provide a significant overall response rate in LGSOC patients with disease progression despite prior systemic treatment.

The European regulatory body’s safety committee has started its review of the vaccine after receiving reports of serious adverse events in elderly patients.

After a successful AI-assisted scientific pilot review, the agency has decided to implement the use of AI across all centers in an accelerated timescale.

The company’s redesigned oral solid dose packaging has been optimized to meet the rising demand for safer, more user-friendly pharmaceutical packaging.

The bispecific monoclonal antibody has demonstrated robust and durable responses in patients with relapse/refractory multiple myeloma.

The new DPI filling technology is an enhanced equivalent to the original filling system for the GSK Diskus DPI and will be available to manufacturers looking to produce generic products from the original Diskus and Ellipta products.

Through this sizable acquisition, Merck will accelerate its growth in the rare tumor segment and boost its U.S. oncology presence.

Supported by clinical trial data, this new indication for upadacitinib provides GCA sufferers with an alternative treatment option that can achieve sustained remission.

As more innovators look to develop orally administered GLP-1s further demand will be placed onto CDMOs to provide the expertise and capabilities needed to support the next generation of these drugs.

This latest investment into expanding its manufacturing capabilities reinforces the company’s commitment to the U.S. and enhances its global biomanufacturing network.

The acquisition will provide PCI with a large-scale manufacturing hub on the West Coast of the U.S., complementing its existing global facilities.

Significant funds, in series A & B funding rounds, have been raised from leading investors to advance the company’s two first-in-class monoclonal antibodies targeting inflammation, autoimmunity, and fibrosis.

Over the next five years, Roche will invest USD 50 billion to expand and upgrade existing facilities and build new facilities across its Pharmaceutical and Diagnostics Division in the U.S.

The CRO is expanding its headquarters to include a comprehensive laboratory and rodent vivarium, which enhances its preclinical research infrastructure in the U.S.

The company’s MLD Advanced uses a combination of proven technologies to enable manufacturers to quickly and efficiently meet the requirements of high outputs.

As the bio/pharma industry faces the looming threat of tariffs, it is clearer than ever that reporting on the key issues and trends set to shape industry is imperative to help stakeholders stay informed.

In case you missed the recent virtual event hosted by Fierce Biotech, where J.D. Mowery, President, CDMO Division, Bora Pharmaceuticals, and Stephen Lam, Chief Executive Officer, Bora Biologics, tackled the issue of biologics’ supply, check out the key takeaways from the discussion here.

Pharmaceutical company, Granules India, has acquired Swiss CDMO, Senn Chemicals AG, for CHF 20 million (USD22 million) through its subsidiary, Granules Peptides as it enters the peptide therapeutics sector.